Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. From Wikipedia
The heart disease drug met primary goals but fell short of investor expectations, leading to a significant stock drop.
